RAPID FIRE Q&A: OPIOID TREATMENT IN U.S. PRISONS — Krista spoke with Mark Crossley, CEO of drugmaker Indivior, which is trying to get its monthly buprenorphine injectable drug into U.S. prison treatment programs, about the state of access to treatment for opioid use disorder in U.S. prisons. The interview has been edited for length and clarity. What kind of access do incarcerated individuals have to treatment for opioid use disorder? The paradigm for treatment has been a rough one, historically. Only about 5 percent of incarcerated patients that suffer from opioid use disorder actually get some form of treatment. Why is that? It can be a stigma-based issue. Some people don't necessarily think you should get treatment. Most of the dosing for [medically assisted treatment] is daily and having to deal with bringing inmates from their cells to the dispensary is a logistical nightmare. And there is no real central funding mechanism for this. Today those that are incarcerated lose their government health care rights. So the funding has to come out of the prison system. There are lots of grants out there people can apply for … but it is an administrative burden on these prisons to apply for the grants and get the money and do that. Why do you think it's important that people in prison have better access to medically assisted treatment? When patients get out of the justice system, they're more at risk. Seventy to 75 percent of patients suffering from opioid use disorder that go through the justice system and go back into the community are reusing within three months. They've not had medically assisted treatment. They've not gotten counseling to deal with their triggers. People coming out of incarceration are somewhere around 10 to 40 times more likely to die of opioid overdoses than the general population. COURT BLOCKS DOJ'S ANTITRUST CASE — Earlier this week, the DOJ lost its antitrust case against UnitedHealth Group, allowing the provider to acquire Change Healthcare. In a redacted opinion released today, we found out why. The government argued that if UnitedHealth Group were to acquire Change, which analyzes operational and financial data and competes with United's OptumInsight, it would give the insurance giant 90 percent market share. It would also, the DOJ argued, create a monopoly in first-pass claims editing, a service that ensures that claims are accurate before they're submitted for reimbursement as OptumInsight's Claims Edit System is the only real competition against Change's ClaimsXten service. All of this is true. However, UnitedHealth Group is divesting of ClaimsXten as part of the acquisition. That divestiture to investment company TPG, wrote Judge Carl Nichols, should preserve competition in the market — especially because the sale includes key talent. The decision is a blow to the Biden administration's antitrust agenda.
|
Comments
Post a Comment